Corcept Sues Hikma to Block Copies of Its Lone Drug, Korlym

Corcept said Hikma’s proposed generic version of Korlym, a treatment for Cushing’s disease and Corcept’s only drug, infringes four patents.

• Corcept is seeking a court order blocking copies until the patents have expired and cash compensation if Hikma makes copies before then, according to complaint filed Friday in federal court in Newark, New Jersey
• Patents cover methods of use and administration of the drug’s active ingredient, mifepristone, Corcept says
  • Two patents expire in June 2037, one in November 2032, and another in March 2033: FDA Orange Book
• Cushing’s disease is caused by an excess of the hormone cortisol and ...